Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Average (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Equity Average for 10 consecutive years, with -$35.4 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 111.77% to -$35.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$35.4 million through Dec 2025, down 111.77% year-over-year, with the annual reading at $87.5 million for FY2025, 66.98% down from the prior year.
  • Equity Average for Q4 2025 was -$35.4 million at Ultragenyx Pharmaceutical, down from $80.2 million in the prior quarter.
  • The five-year high for Equity Average was $1.1 billion in Q1 2021, with the low at -$35.4 million in Q4 2025.
  • Average Equity Average over 5 years is $442.5 million, with a median of $293.6 million recorded in 2024.
  • The sharpest move saw Equity Average surged 384.77% in 2024, then tumbled 111.77% in 2025.
  • Over 5 years, Equity Average stood at $928.1 million in 2021, then crashed by 55.78% to $410.4 million in 2022, then tumbled by 62.63% to $153.4 million in 2023, then soared by 96.22% to $300.9 million in 2024, then plummeted by 111.77% to -$35.4 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at -$35.4 million, $80.2 million, and $147.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.